Advertisement
Australia markets open in 5 hours 18 minutes

  • ALL ORDS

    8,039.90
    +27.80 (+0.35%)
     

  • AUD/USD

    0.6643
    -0.0015 (-0.23%)
     

  • ASX 200

    7,796.00
    +26.60 (+0.34%)
     

  • OIL

    80.59
    -0.70 (-0.86%)
     

  • GOLD

    2,334.70
    -34.30 (-1.45%)
     

  • Bitcoin AUD

    96,030.35
    -320.89 (-0.33%)
     

  • CMC Crypto 200

    1,320.53
    -39.80 (-2.92%)
     

GoodRx (GDRX) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Equity Research
·2-min read

GoodRx Holdings, Inc. (GDRX) reported $197.88 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 7.6%. EPS of $0.08 for the same period compares to $0.07 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $196.2 million, representing a surprise of +0.86%. The company delivered an EPS surprise of -11.11%, with the consensus EPS estimate being $0.09.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how GoodRx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Monthly Active Consumers: 7 compared to the 7 average estimate based on three analysts.

  • Subscribers: 778 versus the two-analyst average estimate of 866.

  • Revenue- Prescription transactions: $145.40 million compared to the $145.51 million average estimate based on five analysts. The reported number represents a change of +7.8% year over year.

  • Revenue- Other: $5.38 million versus $4.89 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +19.4% change.

  • Revenue- Pharma Manufacturer Solutions: $24.51 million versus $23.21 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +20.1% change.

  • Revenue- Subscription: $22.60 million versus $22.56 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -6.2% change.

View all Key Company Metrics for GoodRx here>>>

Shares of GoodRx have returned +8.7% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GoodRx Holdings, Inc. (GDRX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research